On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
FridayDec 29, 2017 2:04 pm

Skinvisible, Inc. (SKVI) Partnership with Quoin Focuses on Population’s Pain Needs

Non-binding proposed merger announced on November 27, 2017 Quoin merger expected to deliver non-opioid relief to post-surgical patients Over-65 population with advanced pain needs expected to double within next 30 years Skinvisible and Quoin proposed merger expected to deliver better results to patients Health professionals are preparing for an expected doubling of the 65 years and older population within the next 30 years, creating medical need to address the pain that often becomes a prevalent companion to age. While modern pharmaceuticals have developed opioids and non-steroidal therapies for reducing chronic pain, the drugs are often accompanied by addiction and unwanted…

Continue Reading

ThursdayDec 28, 2017 1:54 pm

ChineseInvestors.com, Inc. (CIIX) CEO Remains Bullish on Bitcoin and Other Cryptocurrencies

Warren Wang, CEO of CIIX, said in a podcast interview that investors in China and the Chinese-speaking community in the U.S. and Canada want to learn more about bitcoin, cryptocurrencies CIIX doubles down on commitment to its bitcoin division, adding a bitcoin ATM in its California headquarters and broadcasting a daily video from the NYSE called ‘Bitcoin Multimillionaire’ Company’s goal in FY2018 is profit, lower costs and a greater than 100 percent YOY sales increase ChineseInvestors.com, Inc. (OTCQB: CIIX) CEO Warren Wang remains bullish on the future of bitcoin and other cryptocurrencies, and he recently said in a podcast interview…

Continue Reading

ThursdayDec 28, 2017 12:59 pm

Skinvisible, Inc. (SKVI) and Quoin Poised to Tackle Opioid Crisis with Alternative Pain Therapies

A possible larger role for leading drug manufacturers, and the resulting opioid epidemic, is met with increased public and government demands for alternative therapies The Skinvisible and Quoin merger, with expected completion in 2018, will create an enterprise positioned to disrupt the $6 billion U.S. opioid market by producing and delivering non-opioid alternatives for pain management Quoin’s QRX001 is slated to provide alternative and effective pain management in the post-surgical setting, where 50 percent of opioid addictions start A recent article by the Washington Post (http://cnw.fm/J40mp) addressed the opioid crisis, suggesting a larger role by leading pharmaceutical drug manufacturers than…

Continue Reading

WednesdayDec 27, 2017 3:49 pm

World Health Organization Officially Rules CBD Should Not be a Scheduled Drug

The World Health Organization (WHO) announced that “the cannabis compound CBD (Cannabidiol) should not be internationally scheduled as a controlled substance” (www.WHO.int) WHO has issued preliminary findings indicating that cannabidiol (CBD) shows “no indications of abuse or dependence potential” and “a good safety profile” MCOA is committed to the development of high quality CBD-based products The World Health Organization (“WHO”) officially recommended on December 14, 2017, that the chemical compound cannabidiol (CBD) no longer be internationally scheduled as a controlled substance. WHO has issued a preliminary report that found CBD to be non-addictive and generally safe. The CBD pre-review report…

Continue Reading

WednesdayDec 27, 2017 3:07 pm

AppSwarm, Inc. (SWRM) Looking for New Developers of Creative Mobile Apps

Global app revenue approaching $77 billion AppSwarm incubates and accelerates emerging talent in crowded market Company building on gaming bedrock, adding business resources and cannabis industry networks In a crowded mobile app market where large global companies dominate the landscape, AppSwarm, Inc. (OTC: SWRM) is working to befriend smaller developers and creative thinkers who hope to elbow their way in and find an audience. The entrepreneur-incubating company has the expertise to identify promising developers who may need some assistance in getting their products to a solid revenue-building stage, as well as the resources needed to help those developers analyze the…

Continue Reading

WednesdayDec 27, 2017 1:05 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Says Best is yet to Come in 2018

DehydraTECH™ is the company’s newly U.S.-patented disruptive drug delivery platform; LXRP CEO Chris Bunka says company is working on more applications for its technology in the treatment of Alzheimer’s disease, Parkinson’s disease, opioid addiction and more LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in the U.S. (and internationally using the Patent Cooperation Treaty), as well as national filings in 44 countries Company has diverse revenue streams, including out-licensing its technology to third parties with fees ranging from five to 10 percent of gross sales, as well as sales of…

Continue Reading

WednesdayDec 27, 2017 12:24 pm

Medical Cannabis Payment Solutions (REFG) Prepares Seamless Transition for Payment Processing to Support Card Participation in Marijuana Industry

If Visa and MasterCard (or others) choose to participate in the marijuana industry in the future, REFG plans to offer quick, full spectrum payment processing REFG’s StateSourced payment gateway is Financial Crimes Enforcement Network (FinCEN) compliant Medical marijuana sales will grow to $13.3 billion by 2020, and adult recreational marijuana sales are expected to reach $11.2 billion by 2020, according to Forbes Medical Cannabis Payment Solutions (OTC: REFG) is ready for the future with a seamless transition in the event that Visa or MasterCard (or others) choose to participate in the marijuana industry. In the event of a transition, full…

Continue Reading

TuesdayDec 26, 2017 2:38 pm

NeutriSci International, Inc. (OTCQB: NRXCF) (TSX.V: NU) (FRA: IN9) Completes Private Placement, Will Use Proceeds for Neuenergy® Marketing

Neuenergy is a chewable and revolutionary energy tablet powered by blueberries and anti-oxidants with no sugar or calories NeutriSci International names Glen Rehman as new CEO Company sees new opportunities for its product in the cannabinoid field, as well as new strategic partnerships NeutriSci International, Inc. (OTCQB: NRXCF) (TSX.V: NU) (FRANKFURT: IN9) recently announced that it has raised $499,999.95 in a non-brokered private placement (http://cnw.fm/C4cA1), with the proceeds to be used for marketing and advertising of Neuenergy®, its branded blueberry-powered energy chewable tablet (http://cnw.fm/Ll6n9). Funds will also go to the company for general corporate purposes. In addition, the company announced…

Continue Reading

TuesdayDec 26, 2017 1:08 pm

India Globalization Capital, Inc. (NYSE: IGC) Targets February 2018 International Patent Filing for Eating Disorder Drug

Filing for IGC-506 anticipated to be completed in the U.S. in 2019, expanding the company’s patent portfolio; company is looking at pre-clinical trials for three of its combination drugs, possibly creating enhanced valuation IGC has pre-clinical trial scheduled in 2018 for IGC-AD1, a combination-therapy drug designed to treat Alzheimer’s IGC-506 is a combination therapy developed from cannabis extracts and other compounds that’s designed to treat multiple types of eating disorders in humans and animals India Globalization Capital, Inc. (NYSE American: IGC) (FRA: IGS1) anticipates a Patent Cooperation Treaty (“PCT”) filing application by February 28, 2018, for IGC-506, which is designed…

Continue Reading

TuesdayDec 26, 2017 12:33 pm

ChineseInvestors.com (CIIX) Successfully Incubates Spinoff

Multifaceted international company, first and only to offer hemp-infused skin care products in China Now set to spin off new subsidiaries Shareholders likely to benefit from value-add transaction In business for nearly two decades, ChineseInvestors.com (OTCQB: CIIX) began as a specialized investment services company providing real-time commentary, analysis and education-related services in the Chinese language. While building recurring revenues through its unique 100,000+ user base, CIIX maintained a long term vision for value-add opportunities. In 2016, the company identified one of the fastest growing markets in the world and entered the explosive new medical CBD market. Targeting the nearly two…

Continue Reading

Contact us: 303.498.7722